Lipopolysaccharide-induced Cross-Tolerance Against Renal Ischemia–reperfusion Injury is Mediated by Hypoxia-Inducible Factor-2Α-regulated Nitric Oxide Production

Kang He,Xiaosong Chen,Conghui Han,Longmei Xu,Jianjun Zhang,Ming Zhang,Qiang Xia
DOI: https://doi.org/10.1038/ki.2013.342
IF: 19.6
2014-01-01
Kidney International
Abstract:Although the protective effect of lipopolysaccharide (LPS) pretreatment on renal ischemia/reperfusion injury is known, a link to hypoxia-inducible factors (HIFs) has not been established. Here we show that LPS treatment led to HIF-2 alpha accumulation in mouse kidneys and endothelial cells, a result of nuclear factor-kappa B activation. Inactivation of HIF-2 alpha, rather than HIF-1 alpha, completely negated LPS-mediated protection against renal ischemia/reperfusion injury. LPS-stimulated renoprotection was related to inducible/endothelial nitric oxide synthase (iNOS/eNOS) expression, increased production of nitric oxide, and enhanced postischemic microcirculatory recovery. All these effects were lost in HIF-2 alpha knockout mice. Preischemic administration of a nitric oxide donor, rather than erythropoietin, restored the lost preconditioning effect of LPS in HIF-2 alpha knockout mice. In vitro and in vivo studies demonstrated that HIF-2 alpha, in endothelial cells, rather than myeloid cells or hepatocytes, was responsible for the LPS-mediated effects. Thus, our results demonstrated that LPS preconditioning protected against renal ischemia/reperfusion injury by HIF-2 alpha activation in endothelial cells that subsequently improved renal microvascular perfusion and reduced ischemic tubular damage.
What problem does this paper attempt to address?